Proteogenomic characterization identifies clinical subgroups in EGFR and ALK wild-type never-smoker lung adenocarcinoma

참고문헌 (60)

1. Sung, H., "Global cancer statistics 2020 : GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries", CA Cancer J. Clin, 71, pp.209~249 (2021)
2. Zhou, F., "Lung cancer in never smokers-the East Asian experience", Transl. Lung Cancer Res, 7, pp.450~463 (2018)
3. Mok, T. S., "Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma", N. Engl. J. Med, 361, pp.947~957 (2009)
4. Du, Z., "Mechanisms of receptor tyrosine kinase activation in cancer", Mol. Cancer, 17, pp.58~ (2018)
5. Naltet, C., "Immune checkpoint inhibitors in elderly patients treated for a lung cancer : a narrative review", Transl. Lung Cancer Res, 10, pp.3014~3028 (2021)
6. Wilky, B. A., "Immune checkpoint inhibitors : the linchpins of modern immu notherapy", Immunol. Rev, 290, pp.6~23 (2019)
7. Chyuan, I. T., "Targeting the tumor microenvironment for improving therapeutic effectiveness in cancer immunotherapy : focusing on immune checkpoint inhibitors and combination therapies", Cancers, 13, pp.1188~ (2021)
8. Wang, X., "Smoking history as a potential predictor of immune checkpoint inhibitor efficacy in metastatic non-small cell lung cancer", J. Natl Cancer Inst, 113, pp.1761~1769 (2021)
9. Gainor, J. F., "EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer : a retrospective analysis", Clin. Cancer Res, 22, pp.4585~4593 (2016)
10. Shaw, A. T., "Crizotinib versus chemotherapy in advanced ALK-positive lung cancer", N. Engl. J. Med, 368, pp.2385~2394 (2013)
11. Chen, Y. J., "Proteogenomics of non-smoking lung cancer in East Asia delineates molecular signatures of pathogenesis and progression", Cell, 182, pp.226~244 (2020)
12. Gillette, M. A., "Proteogenomic characterization reveals therapeutic vulner abilities in lung adenocarcinoma", Cell, 182, pp.200~225 (2020)
13. Xu, J. Y., "Integrative proteomic characterization of human lung adeno carcinoma", Cell, 182, pp.245~261 (2020)
14. Devarakonda, S., "Genomic profiling of lung adenocarcinoma in never smokers", J. Clin. Oncol, 39, pp.3747~3758 (2021)
15. Zhang, T., "Genomic and evolutionary classification of lung cancer in never smokers", Nat. Genet, 53, pp.1348~1359 (2021)
16. Lehtio, J., "Proteogenomics of non-small cell lung cancer reveals molecular subtypes associated with specific therapeutic targets and immune evasion mechanisms", Nat. Cancer, 2, pp.1224~1242 (2021)
17. Soltis, A. R., "Proteogenomic analysis of lung adenocarcinoma reveals tumor heterogeneity, survival determinants, and therapeutically relevant pathways", Cell Rep. Med, 3, pp.100819~ (2022)
18. Dobin, A., "STAR : ultrafast universal RNA-seq aligner", Bioinformatics, 29, pp.15~21 (2013)
19. Wang, X., "customProDB : an R package to generate customized protein databases from RNA-Seq data for proteomics search", Bioinformatics, 29, pp.3235~3237 (2013)
20. Hundal, J., "pVAC-Seq : a genome-guided in silico approach to identifying tumor neoantigens", Genome Med, 8, pp.11~ (2016)
21. Favero, F., "Sequenza : allele-specific copy number and mutation profiles from tumor sequencing data", Ann. Oncol, 26, pp.64~70 (2015)
22. Yoshihara, K., "Inferring tumour purity and stromal and immune cell admixture from expression data", Nat. Commun, 4, pp.2612~ (2013)
23. Lawrence, M. S., "Mutational heterogeneity in cancer and the search for new cancer-associated genes", Nature, 499, pp.214~218 (2013)
24. Wang, S., "Copy number signature analysis tool and its application in prostate cancer reveals distinct mutational processes and clinical outcomes", PLoS Genet, 17, pp.e1009557~ (2021)
25. Charoentong, P., "Pan-cancer immunogenomic analyses reveal genotype immunophenotype relationships and predictors of response to checkpoint blockade", Cell Rep, 18, pp.248~262 (2017)
26. Bagaev, A., "Conserved pan-cancer microenvironment subtypes predict response to immunotherapy", Cancer Cell, 39, pp.845~865 (2021)
27. Szklarczyk, D., "STRING v11 : protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experi mental datasets", Nucleic Acids Res, 47, pp.D607~D613 (2019)
28. Eid, S., "KinMap : a web-based tool for interactive navigation through human kinome data", BMC Bioinforma, 18, pp.16~ (2017)
29. Tsherniak, A., "Defining a cancer dependency map", Cell, 170, pp.564~576 (2017)
30. Kortleve, D., "Cancer germline antigens and tumor-agnostic CD8(+)T cell evasion", Trends Immunol, 43, pp.391~403 (2022)
31. Consortium, G. T., "The Genotype-Tissue Expression(GTEx)project", Nat. Genet, 45, pp.580~585 (2013)
32. Friedlaender, A., "EGFR and HER2 exon 20 insertions in solid tumours : from biology to treatment", Nat. Rev. Clin. Oncol, 19, pp.51~69 (2022)
33. Huang, L., "KRAS mutation : from undruggable to druggable in cancer", Signal Transduct. Target Ther, 6, pp.386~ (2021)
34. Nyquist, M. D., "Combined TP53 and RB1 loss promotes prostate cancer resistance to a spectrum of therapeutics and confers vulnerability to replication stress", Cell Rep, 31, pp.107669~ (2020)
35. Offin, M., "Concurrent RB1 and TP53 alterations define a subset of EGFR mutant lung cancers at risk for histologic transformation and inferior clinical outcomes", J. Thorac. Oncol, 14, pp.1784~1793 (2019)
36. Otto, W., "Microsatellite instability and manifestations of angiogenesis in stage IV of sporadic colorectal carcinoma", Medicine, 98, pp.e13956~ (2019)
37. Sahu, A., "Discovery of targets for immune-metabolic antitumor drugs identifies estrogen-related receptor alpha", Cancer Discov, 13, pp.672~701 (2023)
38. Tyagi, A., "Inhibition of retinoblastoma protein(Rb)phosphorylation at serine sites and an increase in Rb-E2F complex formation by silibinin in androgen-dependent human prostate carcinoma LNCaP cells : role in prostate cancer prevention", Mol. Cancer Ther, 1, pp.525~532 (2002)
39. Gong, Q., "Restoration of thymocyte development and function in zap-70-", -mice by the Syk protein tyrosine kinase, 1997, pp.7, 369~377
40. Ferrara, R., "Single or combined immune checkpoint inhibitors compared to f irst-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer", Cochrane Database Syst. Rev, 12, pp.CD013257~ (2020)
41. Balkwill, F. R., "The chemokine system and cancer", J. Pathol, 226, pp.148~157 (2012)
42. Jenkins, L., "Cancer-associated fibroblasts suppress CD8+ T-cell Infiltration and confer resistance to immune-checkpoint blockade", Cancer Res, 82, pp.2904~2917 (2022)
43. Suh, J., "Fibroblast growth factor-2, derived from cancer-associated fibroblasts, stimulates growth and progression of human breast cancer cells via FGFR1 signaling", Mol. Carcinog, 59, pp.1028~1040 (2020)
44. Schajnovitz, A., "CXCL12 secretion by bone marrow stromal cells is depen dent on cell contact and mediated by connexin-43 and connexin-45 gap junc tions", Nat. Immunol, 12, pp.391~398 (2011)
45. Funasaka, T., "Galectin-3 in angiogenesis and metas tasis", Glycobiology, 24, pp.886~891 (2014)
46. Gopinathan, G., "Interleukin-6 stimulates defective angiogenesis", Cancer Res, 75, pp.3098~3107 (2015)
47. Natori, T., "G-CSF stimulates angiogenesis and promotes tumor growth : potential contribution of bone marrow-derived endothelial progenitor cells", Biochem. Biophys. Res. Commun, 297, pp.1058~1061 (2002)
48. Skara, L., "Prostate cancer-focus on cholesterol", Cancers, 13, pp.4696~ (2021)
49. Wang, J., "CERS4 predicts positive anti-PD-1 response and promotes immu nomodulation through Rhob-mediated suppression of CD8+Tim3+ exhausted T cells in non-small cell lung cancer", Pharm. Res, 194, pp.106850~ (2023)
50. Tucci, S., "Altered metabolic flexibility in inherited metabolic diseases of mitochondrial fatty acid metabolism", Int J. Mol. Sci, 22, pp.3799~ (2021)
51. Barretina, J., "The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity", Nature, 483, pp.603~607 (2012)
52. Siegmund, D., "TNF receptor associated factor 2(TRAF2)signaling in cancer", Cancers, 14, pp.4055~ (2022)
53. Matas-Rico, E., "Autotaxin impedes anti-tumor immunity by suppressing chemotaxis and tumor infiltration of CD8+ T cells", Cell Rep, 37, pp.110013~ (2021)
54. Mirzaei Bavil, F., "Ghrelin decreases angiogenesis, HIF-1alpha and VEGF protein levels in chronic hypoxia in lung tissue of male rats", Adv. Pharm. Bull, 5, pp.315~320 (2015)
55. Mrozik, H., "4-amino-6-(trichloroethenyl)-1, 3-benzenedisulfonamide, a new, potent fasciolicide", J. Med Chem, 20, pp.1225~1227 (1977)
56. Seo, W., "Runx-mediated regulation of CCL5 via antagonizing two enhancers influences immune cell function and anti-tumor immunity", Nat. Commun, 11, pp.1562~ (2020)
57. Ren, J., "CXCL13 as a novel immune checkpoint for regulatory b cells and its role in tumor metastasis", J. Immunol, 208, pp.2425~2435 (2022)
58. Vredevoogd, D. W., "Augmenting immunotherapy impact by lowering tumor TNF cytotoxicity threshold", Cell, 178, pp.585~599 (2019)
59. Shirakawa, R., "Ral GTPases : crucial mediators of exocytosis and tumourigenesis", J. Biochem, 157, pp.285~299 (2015)
60. La Fleur, L., "Mutation patterns in a population-based non-small cell lung cancer cohort and prognostic impact of concomitant mutations in KRAS and TP53 or STK11", Lung Cancer, 130, pp.50~58 (2019)

관련 논문AI추천